The retinal dysfunction and the delayed visual cortex responses shown by patients Ž . affected by glaucoma can be objectively assessed by Pattern Electroretinogram PERG Ž . and Visual Evoked Potentials VEP recordings. The present study aims to evaluate the effects of nicergoline on the retinal function and on the visual cortical responses in Ž . glaucoma patients. Methods: Sixty patients mean age 44.6" 3.7 with open angle glaucoma were enrolled. The patients were divided into two groups: NG Group, where 30 patients Ž ᮋ . were treated with nicergoline Cebran , 2 cps day for 30 days; and CG Group, where 30 patients were not treated. Simultaneous recordings of PERG and VEP were performed in Ž . NG patients at the baseline, at 30 days after treatment with nicergoline day 30 , and at 45 Ž . days from the end of the treatment day 75 . PERG and VEP were recorded in CG patients at the baseline and after 30 and 75 days. The visual stimulus for recording PERGs and VEPs was a checkerboard whose elements subtended a visual arc of 60Ј and 15Ј with a 70% contrast, and alternated at a frequency of 2 Hz. Results: At the baseline none of the Ž . electrophysiological parameters observed in NG Group patients differed P) 0.05 from those of CG Group patients. At days 30 and 75, in CG Group patients the values of the Ž . PERG and VEP parameters were unmodified P) 0.05 with respect to the baseline. In NG Group patients, the 30-day treatment period with nicergoline induced a significant Ž . P-0.01 improvement of the PERG and VEP parameters. At day 75 all the electrophysi-Ž . ological parameters of NG Group did not differ significantly P) 0.05 from those at the baseline. Conclusion: Treatment with nicergoline induces an improvement of the retinal function and of the visual cortical responses in patients affected by glaucoma. This effect disappears within 45 days after the suspension of the treatment.
Purpose:
The retinal dysfunction and the delayed visual cortex responses shown by patients Ž . affected by glaucoma can be objectively assessed by Pattern Electroretinogram PERG Ž . and Visual Evoked Potentials VEP recordings. The present study aims to evaluate the effects of nicergoline on the retinal function and on the visual cortical responses in Ž . glaucoma patients. Methods: Sixty patients mean age 44.6" 3.7 with open angle glaucoma were enrolled. The patients were divided into two groups: NG Group, where 30 patients Ž ᮋ . were treated with nicergoline Cebran , 2 cps day for 30 days; and CG Group, where 30 patients were not treated. Simultaneous recordings of PERG and VEP were performed in Ž . NG patients at the baseline, at 30 days after treatment with nicergoline day 30 , and at 45 Ž . days from the end of the treatment day 75 . PERG and VEP were recorded in CG patients at the baseline and after 30 and 75 days. The visual stimulus for recording PERGs and VEPs was a checkerboard whose elements subtended a visual arc of 60Ј and 15Ј with a 70% contrast, and alternated at a frequency of 2 Hz. Results: At the baseline none of the Ž . electrophysiological parameters observed in NG Group patients differed P) 0.05 from those of CG Group patients. At days 30 and 75, in CG Group patients the values of the Ž . PERG and VEP parameters were unmodified P) 0.05 with respect to the baseline. In NG Group patients, the 30-day treatment period with nicergoline induced a significant Ž . P-0.01 improvement of the PERG and VEP parameters. At day 75 all the electrophysi-Ž . ological parameters of NG Group did not differ significantly P) 0.05 from those at the baseline. Conclusion: Treatment with nicergoline induces an improvement of the retinal function and of the visual cortical responses in patients affected by glaucoma. This effect disappears within 45 days after the suspension of the treatment.
INTRODUCTION
The clinical definition of glaucoma is based on the Ž detection of an elevated intraocular pressure ) 21 . mmHg along with alterations of the optic nerve head and reduction of the visual field.
That glaucoma adversely affects visual function is common knowledge. The effects of glaucoma may be evaluated through subjective semeiological methods, w x such as the analysis of the visual field 1 , of colour w x w x vision 2 and of contrast sensitivity 3 . However, as these methods are based on cortical psychophysical responses, they cannot provide specific information on the functionality of the various structures that Ž determine a proper visual function different retinal layers, optic nerve, post-chiasmatic visual pathways, . visual cortex .
An objective evaluation of the single structures of the visual system may be obtained by recording the Ž electroretinographic signals, evoked by flash Flash . Ž . ERG or pattern Pattern ERG᎐PERG stimuli, and the bioelectric potentials of the occipital cortex, Ž evoked by patterned stimuli Visual Evoked Poten-. tialsᎏVEPs . Simultaneous recordings of PERGs and VEPs allow us to derive an electrophysiological index for the evaluation of the neural conduction in the post-retinal visual pathway: the retinocortical Ž . w x time RCT 4 . w x Recent studies report normal flash ERG 5, 6 and w x w pathological alteration of PERG 5᎐15 and VEP 9, x 11, 16᎐19 both in patients with glaucoma or ocular hypertension, and in animals with experimentally-induced glaucoma. Furthermore, a delay in RCT has w x been observed in glaucoma patients only 11, 19 . These electrophysical studies support the notion that glaucoma not only induces a dysfunction of the w x inner retinal layers 20 , but also an impairment of Ž . the central nervous system CNS structures that w x contribute to the visual function 19 . These data are confirmed by the results obtained in brain autopsies w x of subjects affected by glaucoma 21 , and by experiw x mental studies on animals 22 .
An important goal in glaucoma therapy is not merely to provide an adequate tonometric compensation, but also to improve the visual system function.
Insofar as glaucoma ultimately leads to alterations of some structures of the central nervous system it is reasonable to explore the therapeutic potential of drugsᎏsuch as citicolineᎏthat are efficacious in w x vascular or cerebral degenerative conditions 23 . Indeed glaucoma patients treated with citocoline exhibit an improvement in the perimetrical indexes w x 24 , as well as in the evoked retinal responses Ž . Ž . PERG , cortical responses VEP and in the postw x retinal neural conduction 25 . Another molecule that could improve the visual function in glaucomatous patients is nicergoline
Nicergoline is a molecule that has been used now for some time in cases of degenerative pathologies of the CNS where the lack of stimulating aminoacids may trigger a process of programmed cellular death with a consequent loss of neurons. Additionally, nicergoline displays antioxidant activity in cat brain homogenates, and as such could contribute to reducing the level of free radicals, thus lowering one of the most potent apoptotic signals. Furthermore, pharmacological and biochemical research in¨i¨o has shown that nicergoline is one of the most potent inhibitors of the alpha-adrenergic receptors and specifically interacts with the D2 dopaminergic presynaptic receptors increasing the turnover of dow x pamine 26᎐33 .
On this basis we undertook a study to evaluate the effect of nicergoline on the retinal cell function and on the post-retinal neural conduction in patients affected by glaucoma.
MATERIALS AND METHODS
Sixty volunteer patients with open-angle glaucoma were enrolled for the study. When the diagnosis of glaucoma was made, all patients had IOP ) 21 Ž . mmHg range 23᎐27, mean 24.10" 1.75 mmHg . Each patient received topical treatment with beta-Ž blocker only and the IOP was -21 mmHg mean . 17.8" 1.5 mmHg in all patients enrolled; filtration surgery had never been performed. Other inclusion criteria were: glaucomatous optic nerve head cup-Ž . ping cuprdisc ratio ) 0.5 , glaucomatous visual field Ž defects Humphrey 24᎐2 perimetry with Mean Devi-. ation between y2 and y4 dB , best corrected visual acuity of 20r20 or better; mean refractive error, when present, between y0.50 and q0.50 spherical equivalent. The mean age was 45.6" 4.3 years. The following exclusion criteria were adopted: presence of any general or ocular pathology that might have interfered with the study; verified intolerance to any ingredient of the drug to be tested; pregnant or nursing women.
CLINICAL PROTOCOL
The patients were divided into two age-matched groups: No other general pharmacological treatments were performed on all glaucoma patients during the whole period of treatment with nicergoline, while the topical treatment with beta-blockers was continued. No differences in the IOP measurements were found Ž between CG and NG patients CG: 17.6 " 1.4 . mmHg; NG: 17.1" 1.6 mmHg .
Informed consent was obtained from each patient enrolled in this study and the research followed the tenets of the Declaration of Helsinki.
To evaluate the efficacy of the drug the retinal function and the neural conduction in the visual pathway was examined by an electrophysiological assessment.
Electrophysiological assessment
In NG patients simultaneous recordings of VEP Ž and PERG were assessed in the basal condition day . 0 , after a 30-day treatment period with nicergoline Ž . Ž day 30 and after a 45-day period of wash-out day . 75 . In CG patients simultaneous recordings of VEP Ž and PERG were assessed in the basal condition day . 0 , and after 30 and 75 days. The electrophysiological examinations were perw x formed using a previously published method 19 . The subjects under examination were seated in a semi-dark, acoustically isolated room in front of the display that was surrounded by a uniform field of luminance of 5 cd m 2 . The subjects were informed of the type of examination and its diagnostic uses.
Prior to the experiment, each subject was adapted to the ambient room light for 10 min and the pupil diameter was approximately 5 mm.
The visual stimuli were checkerboard patterns w Ž .Ž contrast expressed as Lmax y Lmin r Lmax q . 2 x Lmin was 95%, mean luminance 100 cd m generated on a TV monitor and reversed in contrast at the rate of 2 reversals s y1 . At the viewing distance of 114 cm the check edges subtended 60Ј and 15Ј of visual angle and the screen of the monitor subtended 12.5Њ. The refraction of all subjects was corrected for the viewing distance. The stimulation was monocular, after occlusion of the other eye.
VEP recordings AgrAgCl cup shaped electrodes were fixed with collodion in the following positions: active electrode in Oz, reference electrode in Fpz, ground on left arm.
The interelectrode resistance was kept below 3 Ž k ⍀. The bioelectric signal was amplified gain . Ž . 20,000 , filtered band-pass 1᎐100 Hz and averaged Ž200 events free from artifacts were averaged for . Ž every trial by BM 6000 Biomedica Mangoni, Pisa, . Italy . The analysis time was 250 ms.
The transient VEP was distinguished by several waves with three peaks, which in normal subjects and in our experimental condition, appeared after Ž . 75, 100 and 145 ms. These peaks had negative N75 , Ž . Ž . positive P100 and negative N145 polarity, respectively. In the recording session simultaneous VEPs and PERGs were recorded at least twice and the resulting waveforms were superimposed to check the repeatability of the results.
PERG recordings
VEP and PERG signals with signals-to-noise ratio ) 2 were accepted. The noise was measured by recording the bioelectrical signals while the monitor was screened by a cardboard and a noise -0.1 V Ž . mean 0.085 V was observed in all subjects tested.
For all VEPs and PERGs the peak latency and the peak amplitude of each of the waves were measured directly on the displayed records by means of a pair of cursors. Simultaneous recordings of VEPs and PERGs made it possible to derive the retinocor-Ž . tical time RCT as the difference between the VEP w x P100 and the PERG P50 peak latencies 4, 25 .
Statistics
The differences between NG and CG patients and the differences observed in each group with respect to the basal condition and to the examination previously performed, were evaluated by oneway analysis of variance for repeated measures Ž . ANOVA and a P-0.01 was considered significant.
RESULTS
The mean data and statistical results are shown in Table I and in Figs 1 and 2 .
In the basal condition, similar values of VEP and Ž . PERG parameters P) 0.05 were observed in NG and CG patients. In CG patients, after 30 and 75 Ž . days, no significant changes P) 0.05 of VEP and PERG parameters were observed, with respect to the values observed in the basal condition.
VEP recordings
Ž . NG patients: after 30 days of treatment day 30 , a Ž . significant P-0.01 decrease in P100 peak laten-Ž . cies and a significant P -0.01 increase in Table I. N75᎐P100 peak amplitudes, with respect to the basal values, were found. At day 75, NG patients presented an increase in P100 peak latencies and a decrease in N75᎐P100 peak amplitudes, with respect to the values observed at day 30. No differences Ž . P)0.01 were found between VEP parameters with respect to the basal ones.
PERG recordings
NG patients: after 30 days of nicergoline treat-Ž . Ž . ment day 30 , a significant P-0.01 decrease in Ž . P50 peak latencies and a significant P-0.01 increase in P50-N95 peak amplitudes, with respect to the basal values, were found. After a period of 45 Ž . days of wash-out day 75 , an increase in P50 peak latencies and a decrease in P50-N95 peak ampli- Table I. tudes, with respect to the values observed at 30 days, were observed and the PERG parameters were simi-Ž . lar to the basal ones P) 0.05 .
Retinocortical time
NG patients: at day 30, a decrease of RCT, with Ž . respect to the basal values, was found P-0.01 . At day 75, we observed an increase of RCT, with respect to the values observed at day 30, and its values were not significantly modified with respect to basal Ž . ones P) 0.05 .
During the whole period of treatment, no adverse side effects were reported from any of the patients enrolled in the study. No significant changes of the intraocular pressure were found in any of the subjects tested.
DISCUSSION AND CONCLUSION
The aim of the present study was to evaluate the effects of nicergoline on the functional responses of the retina and of the visual cortex in glaucoma patients.
We observed an improvement of the electrophysi-Ž . ological responses of the visual cortex VEP , with a concomitant improvement of the retinal function Ž . PERG and of the post-retinal neural conduction Ž . RCT after the treatment with nicergoline.
The efficacy of nicergoline in the treatment of diabetic and hypertensive retinal ischaemic patholow x gies is recognised 34᎐36 , and the results of the present study indicate that nicergoline has a positive effect on the function of the retina and the visual cortex, but the exact mechanism of action of this molecule on the visual system, is not well known. Treatment with nicergoline improved the VEPs of glaucoma patients. Thus, the electrophysiological data which indicate that nicergoline improves the cortical responses confirms what has been previously w x suggested by the psychophysical analysis 37 .
As the variation of the VEPs observed in glaucoma patients has been ascribed to a dysfunction of Ž the innermost retinal layers ganglion cells and their . fibers correlated to a delay in the post-retinal neuw x ral conduction 11, 19 , in the present study we have evaluated the effect of nicergoline on retinal function and on the neural conduction along the visual pathways.
Retinal function was evaluated by PERG recordings and our results indicate that nicergoline induces Ž an improvement of retinal bioelectric activity PERG . with reduced latency and increased amplitude . However, as no morphological evaluation was conducted, nothing can be said about ulterior effects on Ž the retinal nerve fibers i.e. an increased thickness of . retinal nerve layers fibers .
The observed PERG improvement could be at- ŽVep 100᎐PERG vs 30 days: F s 0.39, Ps 0.536 1, 59 . P50 latencies, ms tributed to the activity on the metabolic rate, to the dopaminergic-like action of nicergoline, or to both.
Recent studies report that treatment with nicergoline during a concomitant treatment with betablockers may induce an improvement of the metabolic parameters of the retina in rats. In fact w x Drago et al. 38 observed that treatment with betablockers alone reduces the level of glucose, pyruvate, citrate and ATP, while the concomitant administration of nicergoline determines a normalization of these biochemical parameters. These results suggest that nicergoline may potentiate cellular metabolic rate and therefore prevent the biochemical alterations correlated to the use of beta-blockers.
Considering that all our patients were treated topically with beta-blockers alone, it could be suggested that nicergoline acts on the retinal cells with a similar mechanism. In fact, if the treatment with nicergoline improves the metabolic rate of the retinal cells in glaucoma patients, it can also determine an improvement of the function of the retinal cells themselves.
Another valuable hypothesis that helps explain the improvement of the PERG is related to nicergoline's effectiveness in facilitating dopaminergic and cholinergic neurotransmission. Considering that levodopa induces an improvement of the retinal function which may be evaluated by PERG recordings w x 39 , we may hypothesize that a similar neuromodulator activity could be considered at the base of nicergoline's ability to improve PERG in glaucoma patients.
Both mechanisms of action could help explain the significant increase in amplitude and decrease in latency of the PERG observed after the treatment with nicergoline.
Along with the retinal function the post-retinal neural conduction was evaluated by measuring the Retinocortical Time.
We observed a reduction of the RCT after the treatment with nicergoline in our glaucoma patients. This reduction may be ascribed to an improvement of the retinal function with a consequent improvement of the neural conduction along the visual pathways. This could induce an increase in the bioelectric activity of those cells in which the cortical potential originates with consequent reduced VEP P100 latencies and increased VEP N75᎐P100 amplitudes after the treatment with nicergoline. It would be of interest to corroborate the independent action of nicergoline on the post-retinal neural conduction and on the visual cortex, for which at present there is no direct evidence in the literature.
Therefore, the effects of nicergoline on the bioelectric responses of the visual cortex may be determined by two sources of improvement: one preva-Ž lent at the retinal level PERG with reduced latency . and increased amplitude and one at the post-retinal Ž . level decreased RCT .
We have previously observed that the perimetrical Ž . indexes Mean Deviation of Humphrey's perimetry are significantly correlated to the parameters of the w x PERG and VEP and to the RCT 40 . Therefore, the sources of cortical improvement mentioned in this study could probably also be used to explain the improvement of the perimetrical condition observed w x after the treatment with nicergoline 37 .
In this study we have evaluated the long-term effects of nicergoline. All electrophysiological parameters of the glaucoma patients treated with nicergoline, observed after 45 days from the end of the treatment, were similar to those observed before the beginning of the treatment. This suggests that the retinal and cortical bioelectrical responses improve after 30 days of treatment, while it is not possible to observe any improvement 45 days after the suspension of the treatment.
Concluding, nicergoline significantly improves the retinal and visual cortical bioelectric responses in glaucoma patients.
As the effects of nicergoline on normal human retinal and cortical responses are unknown at present and on account of nicergoline being effective in w x several other disorders 26᎐31 , we believe that this drug cannot be considered a specific treatment in glaucoma. Nevertheless, our results suggest a potential use of this substance in the medical treatment of glaucoma as a complement of the hypotensive therapy and the absence of collateral effects offers an additional advantage.
Further work will be required to corroborate our conclusions and to determine the effect of various treatment schemes.
